Ciprolet Infusion Solution 200mg 100ml bottle

Infusion Solution

Composition

Ciprofloxacin

Excipients: sodium chloride, lactic acid, disodium edetate, citric acid monohydrate, sodium hydroxide, hydrochloric acid, water d / u.

Packing

100 ml

Mechanism of action

CYPROLET is a broad-spectrum antibacterial drug from the group of fluoroquinolones. Bactericidal effect. The drug inhibits the enzyme DNA gyrase of bacteria, as a result of which DNA replication and synthesis of cellular proteins of bacteria are violated. Ciprofloxacin acts both on the breeding microorganisms and on those in the resting phase.

To ciprofloxacin sensitive Gram-negative aerobic bacteria: Escherichia coli, Salmonella spp., Shigella spp., Citrobacter spp., Klebsiella spp., Enterobacter spp., Proteus mirabilis, Proteus vulgaris, Serratia marcescens, Hafhia alvei, Edwardsiella tarda; spp.; other gram negative bacteria: Haemophilus spp., Pseudomonas aeruginosa, Moraxella catarrhalis, Aeromonas spp., Pasteurella multocida, Plesiomonas shigelloides, Campylobacter jejuni, Neisseria spp.; some intracellular pathogens: Legionella pneumophila, Brucella spp., Chlamydia trachomatis, Listeria monocytogenes, Mycobacterium tuberculosis, Mycobacterium kansasii, Mycobacterium avium-intracellulare.

To ciprofloxacin gram-positive aerobic bacteria are also sensitive: Staphylococcus spp. (S.aureus, S.haemolyticus, S.hominis, S.saprophyticus), Streptococcus spp. (St. pyogenes, St.agalactiae). Most methicillin resistant staphylococci are also resistant to ciprofloxacin.

Sensitivity bacteria Streptococcus pneumoniae, Enterococcus faecalis moderate.

To drug resistant Corynebacterium spp., Bacteroides fragilis, Pseudomonas cepacia, Pseudomonas maltophilia, Ureaplasma urealyticum, Clostridium difficile, Nocardia asteroides. The effect of the drug on Treponema pallidum is not well understood.

Indications and usage

Infectious and inflammatory diseases caused by microorganisms susceptible to ciprofloxacin, including:

- respiratory tract infections;

- infections of upper respiratory tract;

- infections of the kidneys and urinary tract;

- genital infections (gonorrhea, prostatitis, adnexitis) and postpartum infections;

- gastrointestinal infections (including mouth, teeth, jaws);

- infections of the gallbladder and biliary tract;

- infections of the skin, mucous membranes and soft tissues;

- infections of the musculoskeletal system;

- sepsis;

- peritonitis.

Prevention and treatment of infections in patients with reduced immunity (with immunosuppressant therapy).

Contraindications

- pseudomembranous colitis;

- deficiency of glucose-6-phosphate dehydrogenase;

- pregnancy;

- lactation period (breastfeeding);

- children and adolescents up to 18 years (until the completion of the skeleton formation process);

- hypersensitivity to ciprofloxacin or other drugs from the group of fluoroquinolones.

WITH caution the drug should be prescribed for severe cerebral atherosclerosis, impaired cerebral circulation, mental illness, convulsive syndrome, epilepsy, severe renal and / or hepatic insufficiency, as well as for elderly patients.

Dosage and administration

The drug should be administered in / in the drip for 30 min (200 mg) and 60 min (400 mg). The solution for infusion is compatible with 0.9% sodium chloride solution, Ringer's solution, 5% and 10% dextrose solution, 10% fructose solution, as well as a solution containing 5% dextrose solution with 0.225% or 0.45% sodium chloride solution.

Dose Ciprolet depends on the severity of the disease, the type of infection, the condition of the body, the age, body weight and kidney function of the patient.

A single dose, on average, is 200 mg (for severe infections, 400 mg), the frequency of administration is 2 times / day. The duration of treatment depends on the severity of the disease and is 1-2 weeks, if necessary, a longer administration of the drug.

At acute gonorrhea the drug is prescribed in / in a single dose of 100 mg.

For prevention of postoperative infections Injected into / in for 30-60 minutes before surgery at a dose of 200-400 mg.

Adverse reactions

Gastrointestinal: nausea, diarrhea, vomiting, abdominal pain, flatulence, anorexia, cholestatic jaundice (especially in patients with previous liver diseases), hepatitis, hepatonecrosis, increased activity of hepatic transaminases and alkaline phase therapy.

Nervous system: dizziness, headache, fatigue, anxiety, tremor, insomnia, nightmares, peripheral paralgesia (abnormal perception of pain), sweating, increased intracranial pressure, anxiety, confusion, depression, hallucinations, and other manifestations of psychotic reactions (occasionally progressing to conditions in which the patient may harm himself), migraine, syncope, cerebral artery thrombosis.

Special senses: violations of taste and smell, blurred vision (diplopia, change in color perception), tinnitus, hearing loss.

Cardiovascular: tachycardia, cardiac arrhythmias, lowering blood pressure, flushing to the skin of the face.

Hemic and lymphatic: leukopenia, granulocytopenia, anemia, thrombocytopenia, leukocytosis, thrombocytosis, hemolytic anemia.

From the laboratory indicators: hypoprothrombinemia, hypercreatininemia, hyperbilirubinemia, hyperglycemia.

Urogenital: hematuria, crystalluria (primarily with alkaline urine and low diuresis), glomerulonephritis, dysuria, polyuria, urinary retention, albuminuria, urethral bleeding, hematuria, reduced nitrogen-excreting kidney function, interstitial nephritis.

Allergic reactions: pruritus, urticaria, blistering, bleeding, and small scabs, drug fever, punctate hemorrhages (petechiae), swelling of the face or larynx, shortness of breath, eosinophilia, increased photosensitivity, vasculitis, erythema nodosum, exudate, polymorphism, increased photosensitivity, vasculitis, erythema nodosum, exudate, and has a complex pattern. - Johnson (malignant exudative erythema), toxic epidermal necrolysis (Lyell's syndrome).

Musculoskeletal system: arthralgia, arthritis, tendovaginitis, tendon ruptures, myalgia.

Other: general weakness, superinfection (candidiasis, pseudomembranous colitis).

Local reactions: pain and burning at the injection site, phlebitis.

Drug interactions

Due to a decrease in the activity of microsomal oxidation processes in hepatocytes, it increases the concentration and lengthens T_1/2 theophylline (and other xanthines, for example, caffeine), oral hypoglycemic drugs, indirect anticoagulants, helps to reduce the prothrombin index.

NSAIDs (excluding acetylsalicylic acid) increase the risk of seizures.

Metoclopramide accelerates the absorption of ciprofloxacin, which reduces the time to reach its C_max.

Co-administration of uricosuric drugs leads to a slower elimination (up to 50%) and an increase in the plasma concentration of ciprofloxacin.

When combined with other antimicrobial agents (beta-lactams, aminoglycosides, Clindamycin, metronidazole), synergism is usually observed; it can be successfully used in combination with azlocillin and ceftazidime in infections caused by Pseudomonas spp.; with mezlocillin, azlocillin and other beta-lactam antibiotics - for streptococcal infections; with isoxazolylpenicillins and Vancomycin - for staphylococcal infections; with Metronidazole and clindamycin - for anaerobic infections.

Enhances the nephrotoxic effect of cyclosporine, there is an increase in serum creatinine, so these patients need to control this indicator 2 times a week.

At the same time, it enhances the effect of indirect anticoagulants.

The infusion solution is pharmaceutically incompatible with all infusion solutions and drugs that are physically and chemically unstable in an acidic environment (pH of the ciprofloxacin infusion solution is 3.5-4.6). You cannot mix the solution for intravenous administration with solutions having a pH greater than 7.

At a temperature up to 25 ° С

3 years